Braveheart Bio
BRVE
20.39
+1.12
+5.81%
Braveheart Bio
US · BRVE
#2845 by market cap
Listed 2026
20.39
+1.12
+5.81%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Braveheart Bio
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
- Founded
- 2024
- CEO
- Dr. Travis Murdoch, M.D.
- Employees
- 30
- Headquarters
- San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- braveheart.bio
Company profile
- Exchange
- US
- Symbol
- BRVE
- Market-cap rank
- #2845
- Listing date
- 2026-08-06
- Market cap
- 1.83B
- Float cap
- 382.31M
- Shares out
- 89.87M
- Float shares
- 18.75M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Braveheart Bio discussion 0 comments